Cross-Seeding of Misfolded Proteins: Implications for Etiology and Pathogenesis of Protein Misfolding Diseases

1. SotoC (2003) Unfolding the role of protein misfolding in neurodegenerative diseases. Nat Rev Neurosci 4: 49–60.

2. JarrettJT, LansburyPTJr (1993) Seeding “one-dimensional crystallization” of amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie? Cell 73: 1055–1058.

3. SotoC, EstradaL, CastillaJ (2006) Amyloids, prions and the inherent infectious nature of misfolded protein aggregates. Trends Biochem Sci 31: 150–155.

4. KociskoDA, ComeJH, PriolaSA, ChesebroB, RaymondGJ, et al. (1994) Cell-free formation of protease-resistant prion protein. Nature 370: 471–474.

5. MoralesR, GreenKM, SotoC (2009) Cross currents in protein misfolding disorders: interactions and therapy. CNS Neurol Disord Drug Targets 8: 363–371.

6. SotoC (2012) Transmissible proteins: expanding the prion heresy. Cell 149: 968–977.

7. JuckerM, WalkerLC (2011) Pathogenic protein seeding in Alzheimer disease and other neurodegenerative disorders. Ann Neurol 70: 532–540.

8. BrundinP, MelkiR, KopitoR (2010) Prion-like transmission of protein aggregates in neurodegenerative diseases. Nat Rev Mol Cell Biol 11: 301–307.

9. AguzziA (2009) Cell biology: beyond the prion principle. Nature 459: 924–925.

10. WestermarkGT, WestermarkP (2010) Prion-like aggregates: infectious agents in human disease. Trends Mol Med 16: 501–507.

11. KrebsMR, Morozova-RocheLA, DanielK, RobinsonCV, DobsonCM (2004) Observation of sequence specificity in the seeding of protein amyloid fibrils. Protein Sci 13: 1933–1938.

12. O'NuallainB, WilliamsAD, WestermarkP, WetzelR (2004) Seeding specificity in amyloid growth induced by heterologous fibrils. J Biol Chem 279: 17490–17499.

13. MoralesR, EstradaLD, Diaz-EspinozaR, Morales-ScheihingD, JaraMC, et al. (2010) Molecular cross talk between misfolded proteins in animal models of Alzheimer's and prion diseases. J Neurosci 30: 4528–4535.

14. GuoJP, AraiT, MiklossyJ, McGeerPL (2006) Abeta and tau form soluble complexes that may promote self aggregation of both into the insoluble forms observed in Alzheimer's disease. Proc Natl Acad Sci U S A 103: 1953–1958.

15. TsigelnyIF, CrewsL, DesplatsP, ShakedGM, SharikovY, et al. (2008) Mechanisms of hybrid oligomer formation in the pathogenesis of combined Alzheimer's and Parkinson's diseases. PLoS ONE 3: e3135 doi:10.1371/journal.pone.0003135

16. ClintonLK, Blurton-JonesM, MyczekK, TrojanowskiJQ, LaFerlaFM (2010) Synergistic interactions between Abeta, tau, and alpha-synuclein: acceleration of neuropathology and cognitive decline. J Neurosci 30: 7281–7289.

17. MandalPK, PettegrewJW, MasliahE, HamiltonRL, MandalR (2006) Interaction between Abeta peptide and alpha synuclein: molecular mechanisms in overlapping pathology of Alzheimer's and Parkinson's in dementia with Lewy body disease. Neurochem Res 31: 1153–1162.

18. YanJ, FuX, GeF, ZhangB, YaoJ, et al. (2007) Cross-seeding and cross-competition in mouse apolipoprotein A-II amyloid fibrils and protein A amyloid fibrils. Am J Pathol 171: 172–180.

19. GotzJ, ChenF, Van DorpeJ, NitschRM (2001) Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science 293: 1491–1495.

20. LewisJ, DicksonDW, LinWL, ChisholmL, CorralA, et al. (2001) Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 293: 1487–1491.

21. FerrerI (2004) Stress kinases involved in tau phosphorylation in Alzheimer's disease, tauopathies and APP transgenic mice. Neurotox Res 6: 469–475.

22. HamiltonRL (2000) Lewy bodies in Alzheimer's disease: a neuropathological review of 145 cases using alpha-synuclein immunohistochemistry. Brain Pathol 10: 378–384.

23. MasliahE, RockensteinE, VeinbergsI, SagaraY, MalloryM, et al. (2001) beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease. Proc Natl Acad Sci U S A 98: 12245–12250.

24. JohanK, WestermarkG, EngstromU, GustavssonA, HultmanP, et al. (1998) Acceleration of amyloid protein A amyloidosis by amyloid-like synthetic fibrils. Proc Natl Acad Sci U S A 95: 2558–2563.

25. BiesselsGJ, StaekenborgS, BrunnerE, BrayneC, ScheltensP (2006) Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol 5: 64–74.

26. Sims-RobinsonC, KimB, RoskoA, FeldmanEL (2010) How does diabetes accelerate Alzheimer disease pathology? Nat Rev Neurol 6: 551–559.

27. BiesselsGJ, KappelleLJ (2005) Increased risk of Alzheimer's disease in Type II diabetes: insulin resistance of the brain or insulin-induced amyloid pathology? Biochem Soc Trans 33: 1041–1044.

28. FukumotoH, TokudaT, KasaiT, IshigamiN, HidakaH, et al. (2010) High-molecular-weight beta-amyloid oligomers are elevated in cerebrospinal fluid of Alzheimer patients. FASEB J 24: 2716–2726.

29. GaoCM, YamAY, WangX, MagdangalE, SalisburyC, et al. (2010) Aβ40 oligomers identified as a potential biomarker for the diagnosis of Alzheimer's disease. PLoS ONE 5: e15725 doi:10.1371/journal.pone.0015725

30. FerrerI, BlancoR, CarmonaM, PuigB, RiberaR, et al. (2001) Prion protein expression in senile plaques in Alzheimer's disease. Acta Neuropathol (Berl) 101: 49–56.

31. DebatinL, StrefferJ, GeissenM, MatschkeJ, AguzziA, et al. (2008) Association between deposition of beta-amyloid and pathological prion protein in sporadic Creutzfeldt-Jakob disease. Neurodegener Dis 5: 347–354.

32. TsuchiyaK, YagishitaS, IkedaK, SanoM, TakiK, et al. (2004) Coexistence of CJD and Alzheimer's disease: an autopsy case showing typical clinical features of CJD. Neuropathology 24: 46–55.

33. MiyazonoM, KitamotoT, IwakiT, TateishiJ (1992) Colocalization of prion protein and beta protein in the same amyloid plaques in patients with Gerstmann-Straussler syndrome. Acta Neuropathol (Berl) 83: 333–339.

34. MawuenyegaKG, SigurdsonW, OvodV, MunsellL, KastenT, et al. (2010) Decreased clearance of CNS beta-amyloid in Alzheimer's disease. Science 330: 1774.

35. TanziRE, MoirRD, WagnerSL (2004) Clearance of Alzheimer's Abeta peptide: the many roads to perdition. Neuron 43: 605–608.

36. GidalevitzT, KikisEA, MorimotoRI (2010) A cellular perspective on conformational disease: the role of genetic background and proteostasis networks. Curr Opin Struct Biol 20: 23–32.

37. BarnesDE, YaffeK (2011) The projected effect of risk factor reduction on Alzheimer's disease prevalence. Lancet Neurol 10: 819–828.

38. BertramL, LillCM, TanziRE (2010) The genetics of Alzheimer disease: back to the future. Neuron 68: 270–281.